stockportfolio.pro
Stocks / ANIP vs HCM
ANIP vs HCM
ANI Pharmaceuticals, Inc. and HUTCHMED (China) Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ANI Pharmaceuticals, Inc. (ANIP) | HUTCHMED (China) Limited (HCM) | |
|---|---|---|
| Market cap | $1.8B | $1.8B |
| Revenue (latest FY) | $883.37M | $548.51M |
| Net income (latest FY) | $77.18M | $456.91M |
| Revenue growth (5y CAGR) | 33.5% | 8.8% |
| Net margin | 8.7% | 83.3% |
| Return on equity | 14.3% | 36.9% |
| P/E ratio | 20.8 | 4.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 3 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANIP — free Open HCM — freeFrequently asked questions
Which is bigger, ANIP or HCM?
ANI Pharmaceuticals, Inc. is larger by market capitalization — $1.8B versus $1.8B.
Which grows faster, ANIP or HCM?
Over the last five fiscal years, ANI Pharmaceuticals, Inc. grew revenue faster — 33.5%/yr versus 8.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.